Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,603,932
  • Shares Outstanding, K 89,472
  • Annual Sales, $ 233,180 K
  • Annual Income, $ -321,550 K
  • EBIT $ -91 M
  • EBITDA $ -50 M
  • 60-Month Beta 0.89
  • Price/Sales 13.57
  • Price/Cash Flow N/A
  • Price/Book 43.01

Options Overview Details

View History
  • Implied Volatility 93.42% (+3.95%)
  • Historical Volatility 56.06%
  • IV Percentile 94%
  • IV Rank 65.70%
  • IV High 118.60% on 04/10/25
  • IV Low 45.18% on 09/19/25
  • Expected Move (DTE 21) 6.12 (15.41%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 2,359
  • Volume Avg (30-Day) 978
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 55,376
  • Open Int (30-Day) 72,031
  • Expected Range 33.59 to 45.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 7
  • High Estimate 0.28
  • Low Estimate -0.31
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +93.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.45 +18.71%
on 12/02/25
42.13 -5.74%
on 12/24/25
+3.45 (+9.51%)
since 11/26/25
3-Month
22.06 +80.05%
on 09/29/25
42.13 -5.74%
on 12/24/25
+14.41 (+56.96%)
since 09/26/25
52-Week
12.91 +207.59%
on 04/09/25
42.13 -5.74%
on 12/24/25
+21.93 (+123.34%)
since 12/26/24

Most Recent Stories

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting...

TVTX : 39.58 (-1.74%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting...

TVTX : 39.58 (-1.74%)
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

New late-breaking data from DUPLEX Study show significantly more FILSPARI ® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan ...

TVTX : 39.58 (-1.74%)
Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual...

TVTX : 39.58 (-1.74%)
Travere: Q3 Earnings Snapshot

Travere: Q3 Earnings Snapshot

TVTX : 39.58 (-1.74%)
Travere Therapeutics Reports Third Quarter 2025 Financial Results

U.S. net product sales of FILSPARI ® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter ...

TVTX : 39.58 (-1.74%)
Travere Therapeutics to Report Third Quarter 2025 Financial Results

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will...

TVTX : 39.58 (-1.74%)
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Late-breaking poster from DUPLEX Study shows more FILSPARI ® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney...

TVTX : 39.58 (-1.74%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 228,600...

TVTX : 39.58 (-1.74%)
Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on Travere Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $24.64.Elevate Your...

TVTX : 39.58 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 49.06
2nd Resistance Point 45.59
1st Resistance Point 42.94
Last Price 39.58
1st Support Level 36.82
2nd Support Level 33.35
3rd Support Level 30.70

See More

52-Week High 42.13
Last Price 39.58
Fibonacci 61.8% 30.97
Fibonacci 50% 27.52
Fibonacci 38.2% 24.07
52-Week Low 12.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar